US Patent Issued to The United States of America, as represented by the Secretary, Department of Health and Human Services on Feb. 17 for "High affinity nanobodies targeting B7-H3 (CD276) for treating multiple solid tumors" (Maryland Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,865, issued on Feb. 17, was assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services (Bethesda, Md.).

"High affinity nanobodies targeting B7-H3 (CD276) for treating multiple solid tumors" was invented by Mitchell Ho (Urbana, Md.), Ruixue Wang (Bethesda, Md.), Bradley St. Croix (Frederick, Md.) and Dan Li (Rockville, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Single-domain monoclonal antibodies that specifically bind B7H3 (also known as CD276) are described. The single-domain antibodies include camel VHH and rabbit VH domain nanobodies selected from phage display libraries. Chimeric an...